GLP-1 prescription growth reflects FDA approvals of newer, more effective agents like semaglutide and tirzepatide, demonstrated cardiovascular benefits in clinical trials, and expanded indications for both type 2 diabetes and chronic weight management
But Novo and Lillys GLP-1s are set to get even cheaper ($350 per month trending down to $250) after both drugmakers just struck a price-cut deal with the Trump administration
Glucagon-like peptide-1 (GLP-1) agonist therapies are increasingly being used for type 2 diabetes and obesity, but evidence now shows they also reduce inflammation across multiple organs through mechanisms related and unrelated to weight-loss-driven metabolic improvements
The approach involves regular monitoring and support to ensure adherence and effectiveness
Gentle, natural cleansers support a healthier scalp environment for regrowth
Notably, participants consumed inadequate calories from carbohydrates, adequate calories from protein as a percentage of total calories (though critically insufficient in g/kg/day for muscle preservation), and excess calories from fat
:format(webp))
